β2-Microglobulin and Cystatin C in Type 2 Diabetes: Assessment of Diabetic Nephropathy

Abstract

Background: Changes in glomerular filtration rate (GFR) provide a valuable indicator of the progression of diabetic nephropathy (DN). This study was designed to demonstrate the clinical values of serum cystatin C (Cys C) and β2-microglobulin in the assessment of renal function in type 2 diabetics by comparing them with the GFR, estimated from the uptake phase of 99 m technetium dimetiltriamino pentaacetic acid renogram (GFR-DTPA) and creatinine clearances.

Materials and Methods: 68 type 2 diabetic patients with (urinary albumin excretions (UAE) 30 - 300 mg/24 h) (n = 39) and without (UAE < 30 mg/24 h) (n = 29) microalbuminuria and 32 controls were enrolled in the study. Serum Cys C, β2-microglobulin, creatinine, urinary microalbumin levels, creatinine clearances and GFR-DTPA values were determined in all groups. Non-parametric ROC curves, using a cut-off GFR-DTPA of 60 mL/min/1.73 m², were obtained for these markers.

Results: Serum Cys C, β2-microglobulin, glucose and HbA1c concentrations were significantly higher in the group with diabetes compared to controls. In the patients with microalbuminuria, serum Cys C and glucose concentrations increased significantly in comparison to patients with normoalbuminuria, while no differences were observed for β2-microglobulin levels. Serum creatinine concentrations, GFR-DTPA values and creatinine clearances were not different between both diabetic groups and controls.

Cys C was positively correlated with β2-microglobulin and creatinine and negatively with GFR values; β2-microglobulin was also positively correlated with serum creatinine in microalbuminurics. A significant inverse correlation was found between β2-microglobulin and GFR values in both microalbuminurics and normoalbuminurics.

Conclusions: Increased Cys C and β2-microglobulin in diabetics may be early indicators of incipient DN. The diagnostic accuracies of Cys C and β2-microglobulin are superior to that of serum creatinine in distinguishing between mild and moderately reduced GFR.

Key words

Type 2 diabetes - beta 2-microglobulin - cystatin C - diabetic nephropathy

References

• 1 Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A. Structure and expression of the human cystatin C gene.  Biochem J. 1990;  268 287-294
• 2 Bianchi C, Donadio C, Tramonti G, Consani C, Lorusso P, Rossi G. Reappraisal of serum beta2-microglobulin as marker of GFR.  Ren Fail. 2001;  23 419-429
• 3 Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C - A new marker of glomerular filtration rate in children independent of age and height.  Pediatrics. 1998;  101 875-881
• 4 Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, Vera M, Piera C, Darnell A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early impairment.  Am J Kidney Dis. 2000;  36 29-34
• 5 Donadio C, Lucchesi A, Ardini L, Ardini M, Giordani R. Cystatin C, β2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine.  J Pharm Biomed Anal. 2001;  24 835-842
• 6 Finney H, Newman D J, Price C P. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance.  Ann Clin Biochem. 2000;  37 49-59
• 7 Grubb A, Simonsen O, Storfelt G, Truedsson L, Thysell H. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate.  Acta Med Scand. 1985;  218 499-503
• 8 Hallab M, Gallois Y, Chatellier G, Rohmer V, Fressinaud P, Marre M. Comparison of reduction in microalbuminuria by enalapril and hydrocholorothiazide in normotensive patients with insulin dependent diabetes.  Brit Med J. 1993;  306 175-182
• 9 Harmoinen A P, Kouri T T, Wirta O R, Lehtimaki T J, Rantalaiho V, Turjanmaa V M, Pasternack A I. Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes.  Clin Nephrol. 1999;  52 363-370
• 10 Henne V, Frei P, Bürgisser P. Beta2-microglobulin - a rapid and automated determination for a broad range of clinical applications.  Anticancer Res. 1997;  17 2915-2918
• 11 Henskens Y M, Veerman E C, Nieuw Amerongen A V. Cystatins in health and disease.  Biol Chem Hoppe-Seyler. 1996;  377 71-86
• 12 Jacobs C, Selwood N H. Renal replacement therapy for end-stage renal failure in France: Current status and evolutive trends over the last decade.  Am J Kidney Dis. 1995;  25 188-195
• 13 Keevil B G, Kilpatrick E S, Nichols S P, Maylor P W. Biological variation of cystatin C. implications for the assessment of glomerular filtration rate.  Clin Chem. 1998;  44 1535-1539
• 14 Konen J C, Shihabi Z K. Microalbuminuria and diabetes mellitus.  American Family Physician. 1993;  48 421-428
• 15 Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindstrom V, Grubb A. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate.  Clin Chem. 1994;  40 1921-1926
• 16 Larsen K. Creatinine assay by a reaction-kinetic approach.  Clin Chim Acta. 1972;  41 209-217
• 17 Mathiesen E R, Oxenbøll B, Johansen K, Svendsen P A, Deckert T. Incipient nephropathy in type 1 (insulin dependent) diabetes.  Diabetologia. 1984;  26 406-410
• 18 Mogensen C E, Schimitz O. The diabetic kidney: from hyperfiltration and microalbuminuria to end-stage renal failure.  Medicine Clinicals of North America. 1988;  72 1465-1492
• 19 Mojiminiyi O A, Abdella N, George S. Evaluation of serum cystatin C and chromogranin A as markers of nephropathy in patients with type 2 diabetes mellitus.  Scand J Clin Lab Invest. 2000;  60 483-489
• 20 Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, Plebani M. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients.  Kidney Int. 2002;  61 1453-1461
• 21 Newman D J, Thakkar H, Edwards R G, Wilkie M, White T, Grubb A O, Price C P. Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine.  Kidney Int. 1995;  47 312-318
• 22 Nolte S, Mueller B, Pringsheim W. Serum α1-microglobulin and beta2-microglobulin for the estimation of fetal glomerular renal function.  Pediatr Nephrol. 1991;  5 573-577
• 23 Oberbauer R, Nenov V, Weidekamm C, Haas M, Szekeres T, Mayer G. Reduction in mean glomerular pore size coincides with the development of large shunt pores in patients with diabetic nephropathy.  Exp Nephrol. 2001;  9 49-53
• 24 Oddoze C, Morange S, Portugal H, Berland Y, Dussol B. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes.  Am J Kidney Dis. 2001;  38 310-316
• 25 Payne R B. Creatinine clearance: a redundant clinical investigation.  Ann Clin Biochem. 1986;  23 243-250
• 26 Perrone R D, Madias N E, Levey A S. Serum creatinine as an index of renal function: new insights into old concepts.  Clin Chem. 1992;  38 1933-1953
• 27 Piwowar A, Knapik-Kordecka M, Buczynska H, Warwas M. Plasma cystatin C concentration in non-insulin-dependent diabetes mellitus: relation with nephropathy.  Arch Immunol Ther Exp (Warsz). 1999;  47 327-331
• 28 Reddi A S. Glomerular and urinary glycosaminoglycans in diabetic rats.  Clin Chim Acta. 1990;  189 211-220
• 29 Schardijn G HC, Statius van Eps L W. Beta 2-microglobulin: its significance in the evaluation of renal function.  Kidney Int. 1987;  32 635-641
• 30 Schimitz A, Vaeth M, Mogensen C E. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM.  Diabetologia. 1994;  37 1251-1258
• 31 Spencer K. Analytical reviews of clinical biochemistry: the estimation of creatinine.  Ann Clin Biochem. 1986;  23 1-25
• 32 Swan S K. The search continues - an ideal marker of GFR.  Clin Chem. 1997;  43 913-914
• 33 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.  Diabetes Care. 1997;  20 1183-1197
• 34 Vernier R L, Steffes M W, Sisson R S, Mauer S M. Heparan sulfate proteoglycan in the glomerular basement membrane in type I diabetes mellitus.  Kidney Int. 1992;  41 1070-1080